IP Library › Granted Patent US 11,198,719
Granted Patent B2
US 11,198,719 · App. 17/244,097 · Granted Dec 14, 2021

Ultra-long acting insulin-Fc fusion protein and methods of use

Inventors: Todd C. Zion (Marblehead, MA); Thomas M. Lancaster (Wenham, MA)
Assignee: Akston Biosciences Corporation
C07K14/62C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,198,719
App. No.
17/244,097
Granted
Dec 14, 2021
Kind
B2
Abstract

The present disclosure relates to compositions of insulin-Fc fusion proteins and their use to treat diabetes.

Claims (10)

1. A fusion protein comprising an insulin polypeptide and an Fc fragment, wherein the insulin polypeptide and the Fc fragment are connected by a peptide linker, wherein the fusion protein comprises the sequence:

(SEQ ID NO: 34)

FVNQHLCGSDLVEALALVCGERGFFYTDPTGGGPRRGIVEQCCHSICSLY

QLENYCNGGGGAGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS

RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYKSTYRVVS

VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS

RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG.

2. The fusion protein of claim 1 , wherein the fusion protein is a homodimer comprising two identical monomers bound together via one or more disulfide bonds.

3. The fusion protein of claim 2 , wherein the percentage homodimer of insulin-Fc fusion protein is greater than or equal to 80%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2021
From: ZION, TODD C.; LANCASTER, THOMAS M.
To: AKSTON BIOSCIENCES CORPORATION
Reel/Frame 056084/0514 →
Continuity (2)
Provisional Application 63017420 · Apr 29, 2020
Related Publication 20210340212A1 · Nov 4, 2021
Cited By (2)
US 12,195,511 US 12,742,000